Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
Lucrezia Raimondi, Filippo Maria Raimondi, Marta Pietranera, et al.
Cancers (2021) Vol. 13, Iss. 8, pp. 1928-1928
Open Access | Times Cited: 20

Showing 20 citing articles:

Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer
Ana Julia Aguiar de Freitas, Rhafaela Lima Causin, Muriele Bertagna Varuzza, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 9952-9952
Open Access | Times Cited: 68
Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
Erin R. Scheidemann, Ayesha N. Shajahan‐Haq
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 22, pp. 12292-12292
Open Access | Times Cited: 43
Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
Ioana Miruna Stanciu, Andreea Paroşanu, Cristina Orlov‐Slavu, et al.
Diagnostics (2023) Vol. 13, Iss. 5, pp. 987-987
Open Access | Times Cited: 18
Targeting CDK4/6 in breast cancer
Anusha Shanabag, Jessica Armand, Eugene Son, et al.
Experimental & Molecular Medicine (2025)
Open Access
Canine Mammary Cancer: State of the Art and Future Perspectives
E. R. Vazquez, Yulia Lipovka, Alejandro Cervantes-Arias, et al.
Animals (2023) Vol. 13, Iss. 19, pp. 3147-3147
Open Access | Times Cited: 14
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Maxwell R. Lloyd, Komal Jhaveri, Kevin Kalinsky, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 743-761
Closed Access | Times Cited: 4
Circulating Tumor DNA and Survival in Metastatic Breast Cancer
Kyle Dickinson, Archi Sharma, Ramanakumar V. Agnihotram, et al.
JAMA Network Open (2024) Vol. 7, Iss. 9, pp. e2431722-e2431722
Open Access | Times Cited: 4
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
Jamie O. Brett, Taronish D. Dubash, Gabriela N. Johnson, et al.
JCO Precision Oncology (2023), Iss. 7
Closed Access | Times Cited: 9
Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?
Ioanna Ploumaki, Efthymios Triantafyllou, Ioannis‐Alexios Koumprentziotis, et al.
Clinical Breast Cancer (2024) Vol. 24, Iss. 3, pp. e177-e185
Closed Access | Times Cited: 2
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Inês Gomes, Catarina Abreu, Luís Costa, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4835-4835
Open Access | Times Cited: 7
Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options
Constanze Elfgen, Vesna Bjelic‐Radisic
Cancers (2021) Vol. 13, Iss. 23, pp. 5994-5994
Open Access | Times Cited: 17
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
Eriseld Krasniqi, Frauke Goeman, Claudio Pulito, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 14534-14534
Open Access | Times Cited: 10
Modeling breast cancer proliferation, drug synergies, and alternating therapies
Wei He, Diane M. Demas, Ayesha N. Shajahan‐Haq, et al.
iScience (2023) Vol. 26, Iss. 5, pp. 106714-106714
Open Access | Times Cited: 5
A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors
Alessandra Virga, Caterina Gianni, Michela Palleschi, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2183-2183
Open Access | Times Cited: 1
Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
Sasha Main, David W. Cescon, Scott V. Bratman
Cancer Drug Resistance (2022) Vol. 5, Iss. 3, pp. 727-48
Open Access | Times Cited: 6
Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
Federica Villa, Alessandra Crippa, Davide Pelizzoni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14427-14427
Open Access | Times Cited: 3
ECM1 is associated with endocrine resistance in ER+ breast cancers
Tae Won Lee, Kyung‐min Lee
Animal Cells and Systems (2022) Vol. 26, Iss. 3, pp. 99-107
Open Access | Times Cited: 5
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them
Lorenzo Foffano, Linda Cucciniello, Eleonora Nicoló, et al.
The Breast (2024) Vol. 79, pp. 103863-103863
Open Access
Liquid Biopsy and its significance on the Early Detection of Breast Cancer
Farkhonde Hasannejad, Ahmad Fazilat, Keivan Majidzadeh‐A
Deleted Journal (2024) Vol. 17, Iss. 3, pp. 55-81
Closed Access
Modeling Breast Cancer Proliferation, Drug Synergies, and Alternating Therapies
Wei He, Diane M. Demas, Ayesha N. Shajahan‐Haq, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top